VRS Verisante Technology Inc

Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or
"Verisante"), a leader in cancer detection technology, announced today that the
Company is partnering with the BC Cancer Foundation to showcase Verisante
Aura(TM), a device for the detection of skin cancer.


"We are very appreciative of the BC Cancer Foundation's support for Verisante
and for Aura(TM) and also for the Foundation's dedication to raising funds that
support innovative research directed at achieving the highest standard of care
for every patient facing cancer in B.C.," said Thomas Braun, President & CEO of
Verisante Technology, Inc.


Verisante has placed an Aura(TM) at the Foundation's Provincial Office in
Vancouver for display and educational purposes.


"Our unique relationship with the BC Cancer Agency allows our donors to be part
of research discoveries made right here in British Columbia," said Douglas
Nelson, President & CEO of the BC Cancer Foundation. "Verisante Aura(TM) is one
of those 'made in BC' inventions coming out of the leading edge technology and
research efforts of the BC Cancer Agency. Our Foundation is pleased to have the
opportunity to demonstrate and promote this exciting technology."


The BC Cancer Foundation funds the areas of greatest priority and promise, as
identified by the scientists and clinicians at the BC Cancer Agency, who look
for priorities and needs that will have the most significant and timely impact
on cancer care and treatment. The Foundation then partners with donors to raise
the necessary funds in support of this life-saving work. Together with its
partners, the Foundation is funding and finding solutions that are having a
direct impact on improving care for cancer patients in British Columbia.


About the BC Cancer Foundation

The BC Cancer Foundation is the bridge that connects philanthropic support and
research breakthroughs in cancer knowledge. As the fundraising partner of the BC
Cancer Agency and the largest charitable funder of cancer research in this
province, we enable donors to make contributions to leading-edge research that
has a direct impact on improvements to cancer care for patients in British
Columbia. We fund with the goal of finding solutions.


As an independent charitable organization, we raise funds exclusively for the BC
Cancer Agency that support innovative cancer research and compassionate
enhancements to patient care. 


Visit www.bccancerfoundation.com to make a donation or to learn how you can make
a difference in the lives of those affected by cancer.


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative
systems for the early detection of cancer. The Verisante Aura(TM) for skin
cancer detection and the Verisante Core(TM) series for lung, colon and cervical
cancer detection utilize a proprietary cancer detection platform, while the
operating software and probe technology are unique to each device. The cancer
detection platform was developed by the BC Cancer Agency and tested and refined
at the Skin Care Centre at Vancouver General Hospital. This exclusive platform
technology allows Verisante to develop and offer a range of compact,
non-invasive cancer detection devices that offer physicians immediate results
for many of the most common cancers. Aura(TM) has been approved for sale in
Canada, Europe and Australia. Core(TM) has not yet been approved for sale. 


Verisante Aura(TM) was awarded the 2014 North American Technology Innovation of
the Year Award for In Vivo Cancer Detection by Frost & Sullivan, Popular Science
Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for
Innovation in Photonics and an Edison Award for Excellence in Innovation in
2013. Verisante Core(TM) was named one of the top 10 cancer breakthroughs of
2011 by the Canadian Cancer Society. 


The TSX Venture Exchange has neither approved nor disapproved of the contents of
this press release. Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this press release. 


Forward Looking Statements 

This release contains forward-looking statements, including, but not limited to,
statements regarding the future commercialization of medical devices, the market
demand for these products and the proprietary protections the Company will
obtain with regard to the technology, all of which statements are subject to
market risks, and the possibility that the Company will not be able to obtain
patent protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ from those
projected due to a number of risks and uncertainties.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Thomas Braun, President & CEO
Verisante Technology, Inc.
Telephone: (604) 605-0507
Email: info@verisante.com


Website:  www.verisante.com
YouTube:  www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Verisante Technology (TSXV:VRS)
Historical Stock Chart
From Nov 2024 to Dec 2024

Verisante Technology (TSXV:VRS)
Historical Stock Chart
From Dec 2023 to Dec 2024